Covidien releases results from a pair of studies supporting treatment of peripheral artery disease with the EverFlex self-expanding stent combined with directional atherectomy and a drug-coated balloon.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Bay State medical device maker Accellent promotes Jeremy Friedman from his role as CFO to president & COO.
Accellent names new COO, president
Massachusetts medtech manufacturer Accellent Inc. shuffled its C-Suite, promoting Jeremy Friedman from CFO to president and COO of the cardio & vascular business, in addition to his duties as executive vice president.
Ivera Medical claims additional patent infringement by Covidien, filing a 2nd lawsuit over port protection caps.
California medical device maker Ivera Medical announced a 2nd lawsuit against Covidien (NYSE:COV), this time in a district court in Southern California, claiming infringement of patents for disinfecting caps for medical devices.
Covidien says it plans to consolidate its manufacturing and distribution operations as part of a global restructuring aimed at saving up to $300 million a year.
Covidien (NYSE:COV) said its board of directors authorized a restructuring plan aimed at saving up to $300 million a year by fiscal 2018, with manufacturing and distribution operations slated to be closed. Covidien did not reveal how many layoffs would be involved.
Ivera Medical Corp. says Covidien's line of Kendall Disinfectant Caps infringe on 3 patents for valve cleaning systems.
Covidien issues guidance for its fiscal 2014 sales and earnings.
Covidien (NYSE:COV) CFO Charles Dockendorff gave investors a look at what the medical device company expects to see for its fiscal 2014 results.
Speaking at Mansfield, Mass.-based Covidien's annual investor meeting, Dockendorff said net sales for FY2014 are expected to grow between 2% and 5% over fiscal 2013.